
Gout Therapeutics Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type
Description
Gout Therapeutics Market Summary
and Market Overview
Gout therapeutics include NSAIDs, corticosteroids, colchicine, and urate-lowering therapies (ULTs) to manage hyperuricemia and acute gout attacks, affecting 0.5-1% of the global population, with higher rates (2-4%) in high-income countries. The market is driven by rising obesity (650 million people), metabolic syndrome, and dietary shifts, which increase hyperuricemia prevalence (5-10%). Gout’s association with cardiovascular and kidney diseases, elevating heart event risk by 30%, underscores early treatment needs. Novel drugs like pegloticase address refractory cases, while increased diagnosis and health education boost demand. The global gout therapeutics market is estimated at USD 1.5-3.0 billion in 2025, with a CAGR of 5%-10% through 2030.
Regional Market Trends
North America: The U.S. leads with high gout prevalence and advanced treatments, while Canada focuses on lifestyle interventions.
Europe: Germany, France, and the UK drive growth with robust rheumatology care.
Asia Pacific: China and India see rising demand due to dietary changes, with Japan emphasizing ULTs.
Rest of the World: Brazil expands access to generics, while the Middle East addresses metabolic syndrome.
Distribution Channel Analysis
Hospital Pharmacy: Expected growth of 5.5%-10.5%, driven by acute gout management. Trends focus on IV therapies.
Retail Pharmacy: Projected growth of 5.2%-10.2%, linked to chronic ULTs. Advances emphasize patient education.
Online Pharmacy: Anticipated growth of 5.0%-10.0%, covering digital access. Trends highlight subscription models.
Type Analysis
NSAIDs: Expected growth of 4.8%-9.8%, valued for acute relief. Trends focus on low-dose options.
Corticosteroids: Projected growth of 4.7%-9.7%, suited for severe flares. Advances emphasize short-term use.
Colchicine: Anticipated growth of 5.0%-10.0%, critical for acute attacks. Trends highlight generics.
Urate-Lowering Agents: Expected growth of 5.5%-10.5%, favored for chronic management. Trends focus on novel drugs.
Others: Expected growth of 4.5%-9.5%, covering biologics. Developments prioritize refractory cases.
Key Market Players
GSK: Offers colchicine for acute gout.
Takeda: Develops ULTs for chronic management.
Amgen: Focuses on biologics for refractory gout.
Novartis: Provides anti-inflammatory therapies.
Teva: Supplies affordable generics.
Porter’s Five Forces Analysis
Threat of New Entrants: Moderate, due to regulatory barriers, but generics lower entry hurdles.
Threat of Substitutes: Low, as lifestyle changes are insufficient for severe gout, though diet competes.
Bargaining Power of Buyers: High, with generics increasing price competition.
Bargaining Power of Suppliers: Low, with multiple API providers.
Competitive Rivalry: High, with players competing on price and novel therapies.
Market Opportunities and Challenges
Opportunities:
Addressing gout, affecting 0.5-1% globally, with ULTs.
Managing metabolic syndrome, impacting 50% of gout patients.
Leveraging novel drugs like pegloticase for refractory cases.
Utilizing increased diagnosis rates, up to 50% in high-income countries.
Meeting demand driven by obesity and dietary shifts.
Supporting cardiovascular risk reduction in gout patients.
Challenges:
High costs of novel biologics.
Patient adherence issues with long-term ULTs.
Regulatory delays for new drugs.
Competition from generics reducing prices.
Limited awareness in low-income regions.
and Market Overview
Gout therapeutics include NSAIDs, corticosteroids, colchicine, and urate-lowering therapies (ULTs) to manage hyperuricemia and acute gout attacks, affecting 0.5-1% of the global population, with higher rates (2-4%) in high-income countries. The market is driven by rising obesity (650 million people), metabolic syndrome, and dietary shifts, which increase hyperuricemia prevalence (5-10%). Gout’s association with cardiovascular and kidney diseases, elevating heart event risk by 30%, underscores early treatment needs. Novel drugs like pegloticase address refractory cases, while increased diagnosis and health education boost demand. The global gout therapeutics market is estimated at USD 1.5-3.0 billion in 2025, with a CAGR of 5%-10% through 2030.
Regional Market Trends
North America: The U.S. leads with high gout prevalence and advanced treatments, while Canada focuses on lifestyle interventions.
Europe: Germany, France, and the UK drive growth with robust rheumatology care.
Asia Pacific: China and India see rising demand due to dietary changes, with Japan emphasizing ULTs.
Rest of the World: Brazil expands access to generics, while the Middle East addresses metabolic syndrome.
Distribution Channel Analysis
Hospital Pharmacy: Expected growth of 5.5%-10.5%, driven by acute gout management. Trends focus on IV therapies.
Retail Pharmacy: Projected growth of 5.2%-10.2%, linked to chronic ULTs. Advances emphasize patient education.
Online Pharmacy: Anticipated growth of 5.0%-10.0%, covering digital access. Trends highlight subscription models.
Type Analysis
NSAIDs: Expected growth of 4.8%-9.8%, valued for acute relief. Trends focus on low-dose options.
Corticosteroids: Projected growth of 4.7%-9.7%, suited for severe flares. Advances emphasize short-term use.
Colchicine: Anticipated growth of 5.0%-10.0%, critical for acute attacks. Trends highlight generics.
Urate-Lowering Agents: Expected growth of 5.5%-10.5%, favored for chronic management. Trends focus on novel drugs.
Others: Expected growth of 4.5%-9.5%, covering biologics. Developments prioritize refractory cases.
Key Market Players
GSK: Offers colchicine for acute gout.
Takeda: Develops ULTs for chronic management.
Amgen: Focuses on biologics for refractory gout.
Novartis: Provides anti-inflammatory therapies.
Teva: Supplies affordable generics.
Porter’s Five Forces Analysis
Threat of New Entrants: Moderate, due to regulatory barriers, but generics lower entry hurdles.
Threat of Substitutes: Low, as lifestyle changes are insufficient for severe gout, though diet competes.
Bargaining Power of Buyers: High, with generics increasing price competition.
Bargaining Power of Suppliers: Low, with multiple API providers.
Competitive Rivalry: High, with players competing on price and novel therapies.
Market Opportunities and Challenges
Opportunities:
Addressing gout, affecting 0.5-1% globally, with ULTs.
Managing metabolic syndrome, impacting 50% of gout patients.
Leveraging novel drugs like pegloticase for refractory cases.
Utilizing increased diagnosis rates, up to 50% in high-income countries.
Meeting demand driven by obesity and dietary shifts.
Supporting cardiovascular risk reduction in gout patients.
Challenges:
High costs of novel biologics.
Patient adherence issues with long-term ULTs.
Regulatory delays for new drugs.
Competition from generics reducing prices.
Limited awareness in low-income regions.
Table of Contents
93 Pages
- Chapter 1 Executive Summary
- Chapter 2 Abbreviation and Acronyms
- Chapter 3 Preface
- 3.1 Research Scope
- 3.2 Research Sources
- 3.2.1 Data Sources
- 3.2.2 Assumptions
- 3.3 Research Method
- Chapter Four Market Landscape
- 4.1 Market Overview
- 4.2 Classification/Types
- 4.3 Application/End Users
- Chapter 5 Market Trend Analysis
- 5.1 Introduction
- 5.2 Drivers
- 5.3 Restraints
- 5.4 Opportunities
- 5.5 Threats
- Chapter 6 Industry Chain Analysis
- 6.1 Upstream/Suppliers Analysis
- 6.2 Gout Therapeutics Analysis
- 6.2.1 Technology Analysis
- 6.2.2 Cost Analysis
- 6.2.3 Market Channel Analysis
- 6.3 Downstream Buyers/End Users
- Chapter 7 Latest Market Dynamics
- 7.1 Latest News
- 7.2 Merger and Acquisition
- 7.3 Planned/Future Project
- 7.4 Policy Dynamics
- Chapter 8 Historical and Forecast Gout Therapeutics Market in North America (2020-2030)
- 8.1 Gout Therapeutics Market Size
- 8.2 Gout Therapeutics Market by End Use
- 8.3 Competition by Players/Suppliers
- 8.4 Gout Therapeutics Market Size by Type
- 8.5 Key Countries Analysis
- 8.5.1 United States
- 8.5.2 Canada
- 8.5.3 Mexico
- Chapter 9 Historical and Forecast Gout Therapeutics Market in South America (2020-2030)
- 9.1 Gout Therapeutics Market Size
- 9.2 Gout Therapeutics Market by End Use
- 9.3 Competition by Players/Suppliers
- 9.4 Gout Therapeutics Market Size by Type
- 9.5 Key Countries Analysis
- 9.5.1 Brazil
- 9.5.2 Argentina
- 9.5.3 Chile
- 9.5.4 Peru
- Chapter 10 Historical and Forecast Gout Therapeutics Market in Asia & Pacific (2020-2030)
- 10.1 Gout Therapeutics Market Size
- 10.2 Gout Therapeutics Market by End Use
- 10.3 Competition by Players/Suppliers
- 10.4 Gout Therapeutics Market Size by Type
- 10.5 Key Countries Analysis
- 10.5.1 China
- 10.5.2 India
- 10.5.3 Japan
- 10.5.4 South Korea
- 10.5.5 Southest Asia
- 10.5.6 Australia
- Chapter 11 Historical and Forecast Gout Therapeutics Market in Europe (2020-2030)
- 11.1 Gout Therapeutics Market Size
- 11.2 Gout Therapeutics Market by End Use
- 11.3 Competition by Players/Suppliers
- 11.4 Gout Therapeutics Market Size by Type
- 11.5 Key Countries Analysis
- 11.5.1 Germany
- 11.5.2 France
- 11.5.3 United Kingdom
- 11.5.4 Italy
- 11.5.5 Spain
- 11.5.6 Belgium
- 11.5.7 Netherlands
- 11.5.8 Austria
- 11.5.9 Poland
- 11.5.10 Russia
- Chapter 12 Historical and Forecast Gout Therapeutics Market in MEA (2020-2030)
- 12.1 Gout Therapeutics Market Size
- 12.2 Gout Therapeutics Market by End Use
- 12.3 Competition by Players/Suppliers
- 12.4 Gout Therapeutics Market Size by Type
- 12.5 Key Countries Analysis
- 12.5.1 Egypt
- 12.5.2 Israel
- 12.5.3 South Africa
- 12.5.4 Gulf Cooperation Council Countries
- 12.5.5 Turkey
- Chapter 13 Summary For Global Gout Therapeutics Market (2020-2025)
- 13.1 Gout Therapeutics Market Size
- 13.2 Gout Therapeutics Market by End Use
- 13.3 Competition by Players/Suppliers
- 13.4 Gout Therapeutics Market Size by Type
- Chapter 14 Global Gout Therapeutics Market Forecast (2025-2030)
- 14.1 Gout Therapeutics Market Size Forecast
- 14.2 Gout Therapeutics Application Forecast
- 14.3 Competition by Players/Suppliers
- 14.4 Gout Therapeutics Type Forecast
- Chapter 15 Analysis of Global Key Vendors
- 15.1 GSK
- 15.1.1 Company Profile
- 15.1.2 Main Business and Gout Therapeutics Information
- 15.1.3 SWOT Analysis of GSK
- 15.1.4 GSK Gout Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
- 15.2 Takeda
- 15.2.1 Company Profile
- 15.2.2 Main Business and Gout Therapeutics Information
- 15.2.3 SWOT Analysis of Takeda
- 15.2.4 Takeda Gout Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
- 15.3 Amgen
- 15.3.1 Company Profile
- 15.3.2 Main Business and Gout Therapeutics Information
- 15.3.3 SWOT Analysis of Amgen
- 15.3.4 Amgen Gout Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
- 15.4 Novartis
- 15.4.1 Company Profile
- 15.4.2 Main Business and Gout Therapeutics Information
- 15.4.3 SWOT Analysis of Novartis
- 15.4.4 Novartis Gout Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
- 15.5 Regeneron
- 15.5.1 Company Profile
- 15.5.2 Main Business and Gout Therapeutics Information
- 15.5.3 SWOT Analysis of Regeneron
- 15.5.4 Regeneron Gout Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
- 15.6 AstraZeneca
- 15.6.1 Company Profile
- 15.6.2 Main Business and Gout Therapeutics Information
- 15.6.3 SWOT Analysis of AstraZeneca
- 15.6.4 AstraZeneca Gout Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
- 15.7 Merck
- 15.7.1 Company Profile
- 15.7.2 Main Business and Gout Therapeutics Information
- 15.7.3 SWOT Analysis of Merck
- 15.7.4 Merck Gout Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
- 15.8 Zydus Group
- 15.8.1 Company Profile
- 15.8.2 Main Business and Gout Therapeutics Information
- 15.8.3 SWOT Analysis of Zydus Group
- 15.8.4 Zydus Group Gout Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
- Please ask for sample pages for full companies list
- Tables and Figures
- Table Abbreviation and Acronyms
- Table Research Scope of Gout Therapeutics Report
- Table Data Sources of Gout Therapeutics Report
- Table Major Assumptions of Gout Therapeutics Report
- Figure Market Size Estimated Method
- Figure Major Forecasting Factors
- Figure Gout Therapeutics Picture
- Table Gout Therapeutics Classification
- Table Gout Therapeutics Applications
- Table Drivers of Gout Therapeutics Market
- Table Restraints of Gout Therapeutics Market
- Table Opportunities of Gout Therapeutics Market
- Table Threats of Gout Therapeutics Market
- Table Covid-19 Impact For Gout Therapeutics Market
- Table Raw Materials Suppliers
- Table Different Production Methods of Gout Therapeutics
- Table Cost Structure Analysis of Gout Therapeutics
- Table Key End Users
- Table Latest News of Gout Therapeutics Market
- Table Merger and Acquisition
- Table Planned/Future Project of Gout Therapeutics Market
- Table Policy of Gout Therapeutics Market
- Table 2020-2030 North America Gout Therapeutics Market Size
- Figure 2020-2030 North America Gout Therapeutics Market Size and CAGR
- Table 2020-2030 North America Gout Therapeutics Market Size by Application
- Table 2020-2025 North America Gout Therapeutics Key Players Revenue
- Table 2020-2025 North America Gout Therapeutics Key Players Market Share
- Table 2020-2030 North America Gout Therapeutics Market Size by Type
- Table 2020-2030 United States Gout Therapeutics Market Size
- Table 2020-2030 Canada Gout Therapeutics Market Size
- Table 2020-2030 Mexico Gout Therapeutics Market Size
- Table 2020-2030 South America Gout Therapeutics Market Size
- Figure 2020-2030 South America Gout Therapeutics Market Size and CAGR
- Table 2020-2030 South America Gout Therapeutics Market Size by Application
- Table 2020-2025 South America Gout Therapeutics Key Players Revenue
- Table 2020-2025 South America Gout Therapeutics Key Players Market Share
- Table 2020-2030 South America Gout Therapeutics Market Size by Type
- Table 2020-2030 Brazil Gout Therapeutics Market Size
- Table 2020-2030 Argentina Gout Therapeutics Market Size
- Table 2020-2030 Chile Gout Therapeutics Market Size
- Table 2020-2030 Peru Gout Therapeutics Market Size
- Table 2020-2030 Asia & Pacific Gout Therapeutics Market Size
- Figure 2020-2030 Asia & Pacific Gout Therapeutics Market Size and CAGR
- Table 2020-2030 Asia & Pacific Gout Therapeutics Market Size by Application
- Table 2020-2025 Asia & Pacific Gout Therapeutics Key Players Revenue
- Table 2020-2025 Asia & Pacific Gout Therapeutics Key Players Market Share
- Table 2020-2030 Asia & Pacific Gout Therapeutics Market Size by Type
- Table 2020-2030 China Gout Therapeutics Market Size
- Table 2020-2030 India Gout Therapeutics Market Size
- Table 2020-2030 Japan Gout Therapeutics Market Size
- Table 2020-2030 South Korea Gout Therapeutics Market Size
- Table 2020-2030 Southeast Asia Gout Therapeutics Market Size
- Table 2020-2030 Australia Gout Therapeutics Market Size
- Table 2020-2030 Europe Gout Therapeutics Market Size
- Figure 2020-2030 Europe Gout Therapeutics Market Size and CAGR
- Table 2020-2030 Europe Gout Therapeutics Market Size by Application
- Table 2020-2025 Europe Gout Therapeutics Key Players Revenue
- Table 2020-2025 Europe Gout Therapeutics Key Players Market Share
- Table 2020-2030 Europe Gout Therapeutics Market Size by Type
- Table 2020-2030 Germany Gout Therapeutics Market Size
- Table 2020-2030 France Gout Therapeutics Market Size
- Table 2020-2030 United Kingdom Gout Therapeutics Market Size
- Table 2020-2030 Italy Gout Therapeutics Market Size
- Table 2020-2030 Spain Gout Therapeutics Market Size
- Table 2020-2030 Belgium Gout Therapeutics Market Size
- Table 2020-2030 Netherlands Gout Therapeutics Market Size
- Table 2020-2030 Austria Gout Therapeutics Market Size
- Table 2020-2030 Poland Gout Therapeutics Market Size
- Table 2020-2030 Russia Gout Therapeutics Market Size
- Table 2020-2030 MEA Gout Therapeutics Market Size
- Figure 2020-2030 MEA Gout Therapeutics Market Size and CAGR
- Table 2020-2030 MEA Gout Therapeutics Market Size by Application
- Table 2020-2025 MEA Gout Therapeutics Key Players Revenue
- Table 2020-2025 MEA Gout Therapeutics Key Players Market Share
- Table 2020-2030 MEA Gout Therapeutics Market Size by Type
- Table 2020-2030 Egypt Gout Therapeutics Market Size
- Table 2020-2030 Israel Gout Therapeutics Market Size
- Table 2020-2030 South Africa Gout Therapeutics Market Size
- Table 2020-2030 Gulf Cooperation Council Countries Gout Therapeutics Market Size
- Table 2020-2030 Turkey Gout Therapeutics Market Size
- Table 2020-2025 Global Gout Therapeutics Market Size by Region
- Table 2020-2025 Global Gout Therapeutics Market Size Share by Region
- Table 2020-2025 Global Gout Therapeutics Market Size by Application
- Table 2020-2025 Global Gout Therapeutics Market Share by Application
- Table 2020-2025 Global Gout Therapeutics Key Vendors Revenue
- Figure 2020-2025 Global Gout Therapeutics Market Size and Growth Rate
- Table 2020-2025 Global Gout Therapeutics Key Vendors Market Share
- Table 2020-2025 Global Gout Therapeutics Market Size by Type
- Table 2020-2025 Global Gout Therapeutics Market Share by Type
- Table 2025-2030 Global Gout Therapeutics Market Size by Region
- Table 2025-2030 Global Gout Therapeutics Market Size Share by Region
- Table 2025-2030 Global Gout Therapeutics Market Size by Application
- Table 2025-2030 Global Gout Therapeutics Market Share by Application
- Table 2025-2030 Global Gout Therapeutics Key Vendors Revenue
- Figure 2025-2030 Global Gout Therapeutics Market Size and Growth Rate
- Table 2025-2030 Global Gout Therapeutics Key Vendors Market Share
- Table 2025-2030 Global Gout Therapeutics Market Size by Type
- Table 2025-2030 Gout Therapeutics Global Market Share by Type
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.